Tightening Reimbursement for Hyaluronic Acid Injections in the U.S.
First written in FY2019-Q2. 3 of 8 entries say "Mitigated", first in FY2020-Q1. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes increase due to changes in the market environment following changes to the reimbursement system. Our sales increased due to adjustments to shipment timing and the weaker yen.」
In the market environment following the changes to the reimbursement system, local unit sales of Spartz FX and our net sales have continued to increase. - FY2024-Q1Supartz FX sales increased after the system changeAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes increase due to changes in the market environment following changes to the reimbursement system. Our sales increased due to adjustments to shipment timing and the weaker yen.」
Amid continuing changes in the market environment following changes to the reimbursement system, Supartz FX's local unit sales and the company's revenue increased. - FY2020-Q3MitigatedAnnual report
「Local sales volumes and our sales of single-injection Gel-One in the U.S. increased substantially as preferred reimbursement from multiple insurers beginning in 2019 was obtained and initiatives to switch patients from competing products progressed.」
In response to the risk of tighter reimbursement in the United States, Gel-One increased sales and revenue by securing preferred reimbursement from multiple insurers and gaining conversions from competing products. - FY2020-Q2MitigatedAnnual report
「Local sales volumes and our sales of single-injection Gel-One in the U.S. increased substantially as a result of preferred reimbursement from multiple insurers beginning in 2019 and successful initiatives to switch patients from competing products.」
While tighter reimbursement in the United States continued, Gel-One secured preferred reimbursement from multiple insurers from 2019, increasing unit sales and revenue. - FY2020-Q1MitigatedAnnual report
「Local sales volumes and our sales of single-injection Gel-One increased as a result of our commercial partner’s sales expansion initiatives and the product obtaining preferred reimbursement from multiple private insurers in the U.S. beginning in 2019.」
For Gel-One, the company secured preferred reimbursement from multiple private insurers from 2019, increasing local unit sales and the company's revenue. - FY2019WorsenedAnnual report
「Supartz FX, a five-injection treatment to improve joint function, has been strongly affected by reimbursement suspensions, and local sales and the company's revenue fell sharply.」
The description intensified from tighter reimbursement to reimbursement suspensions, with the impact expanding into a sharp decline in Supartz FX's U.S. sales and the company's revenue. - FY2019-Q3MaterialisedAnnual report
「Supartz FX, a five-injection treatment to improve joint function, has been strongly affected by tighter reimbursement, and U.S. sales and the company's revenue fell sharply.」
Tighter reimbursement by certain insurers has actually manifested itself in a sharp decline in Supartz FX's U.S. sales and the company's revenue. - FY2019-Q2First statedAnnual report
「Supartz FX, a five-injection treatment to improve joint function, has performed weakly in the local market under the strong impact of tighter reimbursement, and our sales fell sharply, also reflecting the high shipments in the same period of the previous year.」
For the first time, the company reported that tighter reimbursement by certain insurers had an actual impact on Supartz FX's U.S. sales and the company's revenue.